Potentiation of GLP-1 action through receptor agonists has demonstrated efficacy in treating metabolic disease (61, 62); however, our knowledge of the effects of DPP4 elimination to potentiate endogenous GLP-1 action within the context of chronic liver disease progression is limited. This evidence concerns the gene DPP4 and metabolic disease.